Suppr超能文献

神经甾体生成的药理学。

The pharmacology of neurosteroidogenesis.

作者信息

Costa E, Auta J, Guidotti A, Korneyev A, Romeo E

机构信息

Fidia Georgetown Institute for the Neurosciences, Georgetown University Medical School, Washington, DC 20007.

出版信息

J Steroid Biochem Mol Biol. 1994 Jun;49(4-6):385-9. doi: 10.1016/0960-0760(94)90284-4.

Abstract

In adrenal cortex and other steroidogenic tissues including glial cells, the conversion of cholesterol into pregnenolone is catalyzed by the cytochrome P450scc located in the inner mitochondrial membrane. A complex mechanism operative in regulating cholesterol access to P450scc limits the rate of pregnenolone biosynthesis. Participating in this mechanism are DBI (diazepam binding inhibitor), an endogenous peptide that is highly expressed in steroidogenic cells and some of the DBI processing products including DBI 17-50 (TTN). DBI and TTN activate steroidogenesis by binding to a specific receptor located in the outer mitochondrial membrane, termed mitochondrial DBI receptor complex (MDRC). MDRC is a hetero-oligomeric protein: only the subunit that includes the DBI and benzodiazepine (BZD) recognition sites has been cloned. Several 2-aryl-3-indoleacetamide derivatives (FGIN-1-X) with highly selective affinity (nM) for MDRC were synthesized which can stimulate steroidogenesis in mitochondrial preparations. These compounds stimulate adrenal cortex steroidogenesis in hypophysectomized rats but not in intact animals. Moreover, this steroidogenesis is inhibited by the isoquinoline carboxamide derivative PK 11195, a specific high affinity ligand for MDRC with a low intrinsic steroidogenic activity. Some of the FGIN-1-X derivatives stimulate brain pregnenolone accumulation in adrenalectomized-castrated rats. The FGIN-1-X derivatives that increase brain pregnenolone content, elicit antineophobic activity and antagonize punished behavior in the Vogel conflict test in rats. These actions of FGIN-1-X are resistant to inhibition by flumazenil, a specific inhibitor of BZD action in GABAA receptors but are antagonized by PK 11195, a specific blocker of the steroidogenesis activation via MDRC stimulation. It is postulated that the pharmacological action of FGIN-1-X depends on a positive modulation of the GABA action on GABAA receptors mediated by the stimulation of brain neurosteroid production.

摘要

在肾上腺皮质以及包括神经胶质细胞在内的其他类固醇生成组织中,胆固醇向孕烯醇酮的转化由位于线粒体内膜的细胞色素P450scc催化。一种调节胆固醇进入P450scc的复杂机制限制了孕烯醇酮生物合成的速率。参与该机制的有DBI(地西泮结合抑制剂),一种在内分泌细胞中高度表达的内源性肽以及一些DBI加工产物,包括DBI 17 - 50(TTN)。DBI和TTN通过与位于线粒体外膜的一种特异性受体结合来激活类固醇生成,该受体称为线粒体DBI受体复合物(MDRC)。MDRC是一种异源寡聚蛋白:仅包含DBI和苯二氮䓬(BZD)识别位点的亚基已被克隆。合成了几种对MDRC具有高选择性亲和力(纳摩尔级)的2 - 芳基 - 3 - 吲哚乙酰胺衍生物(FGIN - 1 - X),它们可刺激线粒体制剂中的类固醇生成。这些化合物可刺激垂体切除大鼠的肾上腺皮质类固醇生成,但对完整动物无效。此外,这种类固醇生成受到异喹啉甲酰胺衍生物PK 11195的抑制,PK 11195是一种对MDRC具有特异性高亲和力且内在类固醇生成活性较低的配体。一些FGIN - 1 - X衍生物可刺激去肾上腺 - 去势大鼠大脑中孕烯醇酮的积累。增加大脑孕烯醇酮含量的FGIN - 1 - X衍生物在大鼠的Vogel冲突试验中引发抗恐惧活性并拮抗受罚行为。FGIN - 1 - X的这些作用对氟马西尼(一种GABAA受体中BZD作用的特异性抑制剂)的抑制具有抗性,但被PK 11195拮抗,PK 11195是通过刺激MDRC激活类固醇生成的特异性阻滞剂。据推测,FGIN - 1 - X的药理作用取决于通过刺激脑内神经甾体生成介导的GABA对GABAA受体作用的正向调节。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验